Jayashree Gowda, MD
Endocrinology, Diabetes & Metabolism · Moline, ILNPI 1811334485
Payments from drug & device makers
Across 182 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$496
- Novo Nordisk$345
- Lilly USA, LLC$322
- Dexcom, Inc.$282
- AstraZeneca$267
- Sanofi-aventis U.S. LLC$210
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,222100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 25 | $496 |
| Novo Nordisk | 21 | $345 |
| Lilly USA, LLC | 20 | $322 |
| Dexcom, Inc. | 22 | $282 |
| AstraZeneca(2 entities) | 12 | $267 |
| Sanofi-aventis U.S. LLC | 14 | $210 |
| Boehringer Ingelheim | 11 | $177 |
| Abbott | 10 | $176 |
| Tandem Diabetes Care, Inc. | 5 | $114 |
| Corcept Therapeutics | 4 | $110 |
| AbbVie | 6 | $98 |
| Mannkind Corporation | 4 | $75 |
| Merck | 5 | $70 |
| Xeris Pharmaceuticals, Inc. | 3 | $55 |
| Sequel Med Tech, LLC | 2 | $47 |
| Ascensia Diabetes Care US Inc. | 2 | $47 |
| Antares Pharma, Inc. | 3 | $45 |
| Bayer | 2 | $44 |
| Medtronic | 1 | $37 |
| Madrigal Pharmaceuticals | 1 | $30 |
| Averitas Pharma Inc. | 1 | $29 |
| Insulet Corporation | 2 | $28 |
| Almatica Pharma LLC | 1 | $24 |
| BETA Bionics, Inc. | 1 | $23 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Bigfoot Biomedical Inc | 1 | $15 |
How this compares
$3,222 in reported general payments places this provider in the 70th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 310 | $529,806 |
| JardianceEmpagliflozin | 167 | $257,586 |
| TrulicityDulaglutide | 160 | $222,910 |
| MounjaroTirzepatide | 115 | $145,496 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 63 | $92,172 |
| Humalog Kwikpen U-100Insulin Lispro | 158 | $79,122 |
| Tresiba Flextouch U-100Insulin Degludec | 75 | $76,614 |
| JanuviaSitagliptin Phosphate | 53 | $63,430 |
| FarxigaDapagliflozin Propanediol | 48 | $58,296 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 82 | $50,108 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 268 | $49,917 |
| ProliaDenosumab | 28 | $47,660 |
| Novolog FlexpenInsulin Aspart | 91 | $38,569 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 41 | $37,506 |
| RybelsusSemaglutide | 19 | $36,235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $345 | $571,012343 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30 | $322 | $380,045312 claims |
| Boehringer IngelheimJardiance, Tradjenta | $177 | $274,367181 claims |
| MerckJanuvia | $70 | $63,43053 claims |
| AstraZenecaFarxiga | $267 | $58,29648 claims |
| AmgenProlia | $496 | $47,66028 claims |
| Sanofi-aventis U.S. LLCLantus | $210 | $5,69519 claims |
| AbbVieSynthroid | $98 | $2,98633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Moline
- Rameshkumar RamanMoline$103K
- Liana BillingsSkokie$3.4M
- Leon FogelfeldChicago$1.5M
- Grazia AleppoChicago$1.4M
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Hiralal MaheshwariMcHenry$642K
- Wenyu HuangChicago$639K
- Babak PazookiJoliet$582K
- Silvana PannainChicago$575K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.